FDA: Arpida Skin Disease Drug Less Effective Than Rival
Tuesday November 18th, 2008 / 15h37
By Jared A. Favole Of DOW JONES NEWSWIRES WASHINGTON -(Dow Jones)- Arpida Ltd.'s (ARPN.EB) proposed drug to treat complicated skin diseases achieved lower cure rates in clinical trials than another drug, federal regulators said Tuesday. Patients taking Arpida's iclaprim had lower cure rates than patients taking the rival drug Zyvox, generically known as linezolid, according to documents posted on the Food and Drug Administration's Web site Tuesday. Arpida, a Swiss biotech company, wants the FDA to approve iclaprim to treat complex skin diseases caused by powerful bacteria that are largely immune to antibiotics already on the market. A panel of outside medical experts will discuss iclaprim at an FDA meeting Thursday. The panel may recommend approval for the drug, but the FDA doesn't have to follow the panel's advice. -By Jared A. Favole, Dow Jones Newswires; 202.862.9207; jared.favole@dowjones.com Click here to go to Dow Jones NewsPlus, a web front page of today's most important business and market news, analysis and commentary: http://www.djnewsplus.com/al?rnd=ca%2BNpgo7zosg6xjniF472A%3D%3D. You can use this link on the day this article is published and the following day.
Les Bourses européennes ont clôturé en ordre dispersé vendredi mais sur une note globalement négative pour la troisième séance d'affilée, dans des échanges peu animés en l'absence...
Wall Street a clôturé en forte baisse jeudi, après la publication de chiffres de l'emploi pires que prévu et qui font douter du scénario d'une reprise rapide. La clôture a été...
La Bourse de Tokyo a fini en baisse de 0,61% vendredi, au lendemain de chiffres de l'emploi américain venus raviver les inquiétudes des investisseurs quant à l'état de l'économie...
Un consortium emmené par le britannique BP et comprenant le chinois CNPC a remporté le contrat d'exploitation du plus important champ pétrolifère d'Irak, a annoncé le ministre...
